<DOC>
	<DOC>NCT00292747</DOC>
	<brief_summary>The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400 mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg administered alone, in the treatment of primary and secondary dysmenorrhoea.</brief_summary>
	<brief_title>Drotaverine in Dysmenorrhoea Treatment</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Drotaverin</mesh_term>
	<mesh_term>Papaverine</mesh_term>
	<criteria>History of at least 6 months of dysmenorrhea, with presence of moderate to severe pain in each of the last 3 cycles With regular menstrual cycles (2535 days) Using an adequate barrier contraception method (except for virgins) Evidence of clinically relevant gynecological, cardiovascular, hematologic, hepatic, gastrointestinal, renal, pulmonary, endocrinologic, neurologic or psychiatric disease, based on a clinical assessment and routine laboratory investigations Proven hypersensitivity to drotaverine hydrochloride or ibuprofen or proven intolerance to lactose Any described contraindication to either drotaverine hydrochloride or ibuprofen (see Summary of Product Characteristics) Oestroprogestative contraception within the last 2 months Regular use of sedative, hypnotics, tranquillizers or any other addictive agents History or evidence of acute or chronic alcohol abuse Heavy smoking (&gt; 10 cigarettes/day) Need of a permanent treatment with other antispasmodics and/or analgesic agents during the trial Lactation Pregnancy Participation in another clinical trial in the last 3 months prior to the start of this study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>